Physician profile

Tucker James Harrison

Interventional Cardiology · Tulsa, OK

NPI 1396004636

$19,498.25

in general payments reported to CMS, 2019-2025

31 companies · $2,803 in 2025

The $2,803 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

See the full distribution for Interventional Cardiology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$7,493.65
Travel and Lodging$3,080.35

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Inari Medical, INC. $4,918.16 2020-2025 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Penumbra, INC. $4,167.98 2022-2025 Indigo System, Penumbra System
Boston Scientific Corporation $2,364.30 2019-2025 General - Balloon Catheters, Peripheral Rotalink Plus, Ekosonic
Abiomed $2,106.45 2022-2025 Impella
Stryker Corporation $1,164.25 2025 Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever
Shockwave Medical, INC $1,064.41 2019-2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Abbott Laboratories $757.42 2020-2024 Mitraclip, Confirm Rx, Assurity
Cardiovascular Systems INC. $653.97 2019-2022
Imperative Care, INC $360.93 2024-2025 Symphony Catheter
Angiodynamics, INC. $317.35 2021-2025 Alphavac, Venacure 1470 Pro
Bard Peripheral Vascular, INC. $306.17 2022-2024 Venclose Maven Catheter
Surmodics, INC. $299.99 2023-2025 Pounce Venous Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy
Novartis Pharmaceuticals Corporation $224.51 2021-2025
Impulse Dynamics (USA) INC. $147.72 2023 Optimizer
Amgen INC. $141.47 2021-2025 Repatha, Repatha
Show all 31 companies
CompanyGeneral paymentsYearsTop products
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $66.61 2022-2023 Lifevest
Boehringer Ingelheim Pharmaceuticals, INC. $52.71 2022-2023 Jardiance
Silk Road Medical, INC. $52.10 2022
Novo Nordisk INC $38.95 2023 Ozempic, Rybelsus
Atricure, INC. $38.08 2021
Kiniksa Pharmaceuticals International, Plc $35.44 2024 Arcalyst
Philips North America LLC $35.43 2024-2025 Mcot, (Ck4) Mcot
E.R. Squibb & Sons, L.L.C. $28.20 2021
Mozarc Medical US LLC $24.63 2025 Palindrome
Kestra Medical Technology Services, INC. $22.53 2025 Assure Wcd
Astrazeneca Pharmaceuticals LP $20.60 2023 Andexxa
Baxter Healthcare $20.06 2024 Hillrom - Carnation Ambulatory Monitor
Pfizer INC. $19.02 2022
Janssen Pharmaceuticals, INC $17.46 2021
Bridgebio Pharma, INC. $16.30 2025 Attruby
Merck Sharp & Dohme LLC $15.05 2023 Verquvo

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tucker James Harrison

$19,498.25

in general payments reported 2019-2025

Years
2019-2025
Top company
Inari Medical, INC.
Context
The $2,803 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/1379819/tucker-james-harrison

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.